(NASDAQ: IMTX) Immatics Nv's forecast annual revenue growth rate of 24.17% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.63%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.32%.
Immatics Nv's revenue in 2026 is $56,783,529.On average, 13 Wall Street analysts forecast IMTX's revenue for 2026 to be $5,919,521,866, with the lowest IMTX revenue forecast at $2,078,107,196, and the highest IMTX revenue forecast at $9,150,375,234. On average, 12 Wall Street analysts forecast IMTX's revenue for 2027 to be $8,592,235,863, with the lowest IMTX revenue forecast at $2,207,352,056, and the highest IMTX revenue forecast at $16,583,295,424.
In 2028, IMTX is forecast to generate $15,584,463,256 in revenue, with the lowest revenue forecast at $6,218,098,945 and the highest revenue forecast at $26,634,630,681.